Mesoblast Limited
MEOBF
$1.55
-$0.04-2.52%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1,053.16% | 613.64% | 191.39% | 68.54% | -39.71% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1,053.16% | 613.64% | 191.39% | 68.54% | -39.71% |
| Cost of Revenue | 171.34% | 98.06% | 29.88% | 12.92% | -25.94% |
| Gross Profit | -11.50% | -6.40% | -1.68% | -1.27% | 22.74% |
| SG&A Expenses | 60.78% | 60.73% | 60.66% | 49.77% | 5.10% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -1,950.00% | -172.06% | 148.05% | 134.53% | 101.63% |
| Total Operating Expenses | 138.70% | 78.47% | 24.68% | 0.30% | -31.95% |
| Operating Income | -37.78% | -21.84% | -7.71% | 7.25% | 30.97% |
| Income Before Tax | 9.13% | -2.22% | -15.50% | -24.49% | -12.34% |
| Income Tax Expenses | 357.72% | 1,413.24% | 272.77% | 221.45% | 152.56% |
| Earnings from Continuing Operations | 8.69% | -2.72% | -16.13% | -25.05% | -12.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8.69% | -2.72% | -16.13% | -25.05% | -12.76% |
| EBIT | -37.78% | -21.84% | -7.71% | 7.25% | 30.97% |
| EBITDA | -30.18% | -16.13% | -3.75% | 9.36% | 31.03% |
| EPS Basic | 20.35% | 12.11% | 3.42% | -3.27% | 16.76% |
| Normalized Basic EPS | 11.20% | 9.68% | 8.13% | 7.93% | 31.03% |
| EPS Diluted | 20.13% | 12.00% | 3.42% | -3.27% | 16.83% |
| Normalized Diluted EPS | 11.20% | 9.68% | 8.13% | 7.93% | 31.03% |
| Average Basic Shares Outstanding | 14.51% | 18.21% | 22.41% | 22.82% | 7.56% |
| Average Diluted Shares Outstanding | 14.51% | 18.21% | 22.41% | 22.82% | 7.56% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |